Pennington Biomedical Research Center and Compellis Pharmaceuticals Complete Phase I Study of Novel and Patented Obesity Therapy
Published: Jul 22, 2010
BOSTON, MA--(Marketwire - July 22, 2010) -
The Pennington Biomedical Rese
For this pilot study subjects were blindly administered either the drug or an inert saline solution via a nasal spray. Blood pressure was checked on a frequent basis. No significant adverse events were reported. Smell testing documented a clear trend for temporary reduction in smell perception that spontaneously reversed over time.
"Finding a significant reduction in blood pressure as a result of nasal administration would have been a concern," said Dr. Frank Greenway, principle investigator. "We are pleased that no significant adverse events were reported and that the drug administration was well tolerated. Based on these encouraging results Phase 2 studies are now being planned for the second half of 2010 and will incorporate a change in eating behavior as an endpoint."
About Compellis Pharmaceuticals, Inc.
Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity and related disorders. The company reformulates FDA approved products and identifies proprietary delivery methods to treat broad metabolic disorders and improve quality of life. For more information, please visit www.compellis.com.
About The Pennington Biomedical Research Institute
The Pennington Biomedical Research Institute is recognized as one of the world's outstanding obesity and nutrition research centers. The Pennington Center's mission is to promote healthier lives through research, education in nutrition and preventive medicine. For more information please visit www.pbrc.edu.
For more information contact: